Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/99043
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Thazhath, S. | - |
dc.contributor.author | Wu, T. | - |
dc.contributor.author | Bound, M. | - |
dc.contributor.author | Checklin, H. | - |
dc.contributor.author | Standfield, S. | - |
dc.contributor.author | Jones, K. | - |
dc.contributor.author | Horowitz, M. | - |
dc.contributor.author | Rayner, C. | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | American Journal of Clinical Nutrition, 2016; 103(1):66-70 | - |
dc.identifier.issn | 0002-9165 | - |
dc.identifier.issn | 1938-3207 | - |
dc.identifier.uri | http://hdl.handle.net/2440/99043 | - |
dc.description.abstract | BACKGROUND: Resveratrol has been reported to lower glycemia in rodent models of type 2 diabetes associated with the stimulation of glucagon-like peptide 1 (GLP-1), which is known to slow gastric emptying, stimulate insulin secretion, and suppress glucagon secretion and energy intake. OBJECTIVE: We evaluated the effects of 5 wk of resveratrol treatment on GLP-1 secretion, gastric emptying, and glycemic control in type 2 diabetes. DESIGN: Fourteen patients with diet-controlled type-2 diabetes [mean ± SEM glycated hemoglobin (HbA1c): 6.4 ± 0.2% (46.4 ± 2.2 mmol/mol)] received resveratrol (500 mg twice daily) or a placebo over two 5-wk intervention periods with a 5-wk washout period in between in a double-blind, randomized, crossover design. Before and after each intervention period (4 visits), body weight and HbA1c were measured, and patients were evaluated after an overnight fast with a standardized mashed-potato meal labeled with 100 μg (13)C-octanoic acid to measure blood glucose and plasma GLP-1 concentrations and gastric emptying (breath test) over 240 min. Daily energy intake was estimated from 3-d food diaries during the week before each visit. RESULTS: Fasting and postprandial blood glucose and plasma total GLP-1 as well as gastric emptying were similar at each assessment, and the change in each variable from weeks 0 to 5 did not differ between resveratrol and placebo groups. Similarly, changes in HbA1c, daily energy intake, and body weight after 5 wk did not differ between the 2 treatments. CONCLUSIONS: In patients with diet-controlled type 2 diabetes, 5 wk of twice-daily 500 mg-resveratrol supplementation had no effect on GLP-1 secretion, glycemic control, gastric emptying, body weight, or energy intake. Our observations do not support the use of resveratrol for improving glycemic control. This trial was registered at www.anzctr.org.au as ACTRN12613000717752. | - |
dc.description.statementofresponsibility | Sony S Thazhath, Tongzhi Wu, Michelle J Bound, Helen L Checklin, Scott Standfield, Karen L Jones, Michael Horowitz, and Christopher K Rayner | - |
dc.language.iso | en | - |
dc.publisher | American Society for Nutrition | - |
dc.rights | © 2016 American Society for Nutrition | - |
dc.source.uri | http://dx.doi.org/10.3945/ajcn.115.117440 | - |
dc.subject | blood glucose; GLP-1; HbA1c; incretin; resveratrol | - |
dc.title | Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.3945/ajcn.115.117440 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Wu, T. [0000-0003-1656-9210] | - |
dc.identifier.orcid | Bound, M. [0000-0003-0211-5832] | - |
dc.identifier.orcid | Jones, K. [0000-0002-1155-5816] | - |
dc.identifier.orcid | Horowitz, M. [0000-0002-0942-0306] | - |
dc.identifier.orcid | Rayner, C. [0000-0002-5527-256X] | - |
Appears in Collections: | Aurora harvest 7 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.